MedTrace Logo

Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma

NCT00652587 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2008-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether hepatectomy combining with adjuvant transcatheter arterial chemoembolization (TACE) for Stage IIIA hepatocellular carcinoma (HCC) resulting better long-term survival outcome when compared with hepatectomy alone.

Conditions

Interventions

PROCEDURE

hepatectomy and transcatheter arterial chemoembolization

partial hepatectomy with adjuvant transcatheter arterial chemoembolization

PROCEDURE

hepatectomy

hepatectomy alone

Sponsors & Collaborators

  • Ministry of Health, China

    collaborator OTHER_GOV

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • GUO Rong-ping, MD · Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652587 on ClinicalTrials.gov